Notes from the last few management interviews.
07.07.2022 (ET interview)
- Growth guidance: consumer (15-20%), scientific (12-15%)
- In consumer division, currently manufacture 40-45% of products, which will increase to 75-80% in next 2-years with upcoming capex
- In scientific division, currently manufacture 80% of products, which will increase to 95% in next 2-years with their backward integration efforts
- Demerger timeline: might take 9 more months
15.12.2022 (CNBC)
- Demand is robust in scientific and consumer division
- Inflation has cooled with raw material prices stagnating, freight costs have come down
- Margins were impacted due to delay in capex which resulted in buying more from outside. There will be one more quarter of margin pain
- Growth momentum in H1 will continue in H2 in both consumer and scientific division
- Demerger and listing should potentially be done by June 2023
- EBITDA target for consumer division is 20% while maintaining 20% sales growth
- EBITDA target for scientific division should be maintained at 25% while maintaining 12-15% sales growth
Disclosure: Not invested (no transactions in last-30 days)
| Subscribe To Our Free Newsletter |
